 Reported interim readouts for lead CAR-T product candidates: FasTCAR-enabled dual-targeting BCMACD19 autologous CAR-T product candidate GC012F for the treatment of multiple myeloma and TruUCAR-enabled CD7-directed CAR-T product candidate GC027 for the treatment of T-ALL 